Last updated: February 25, 2026
What Is the Therapeutic Use and Market Context?
NDC 54436-0112 is a biologic drug used for specific immune-related indications. It is marketed primarily for autoimmune conditions, such as rheumatoid arthritis and psoriasis. The drug’s market share is influenced by existing therapies, patent status, and regulatory developments.
Market Size and Competitive Landscape
Indications and Market Demand
- Primary indications: Rheumatoid arthritis, psoriasis, inflammatory bowel disease.
- Market size: The global autoimmune therapy market was valued at approximately $28 billion in 2022 and is projected to reach $45 billion by 2030, growing at a CAGR of 6.4% (Research and Markets, 2023).
- Estimate for NDC 54436-0112: Captures an estimated 10-15% of the biologic autoimmune segment due to moderate competition.
Competitors
| Drug Name |
Approval Year |
Market share (2022) |
Pricing (per dose) |
Patent status |
| Adalimumab (Humira) |
2002 |
30% |
$2,500 |
Patent expired in 2016 |
| Etanercept (Enbrel) |
1998 |
15% |
$2,200 |
Patent expired in 2028 |
| Ustekinumab (Stelara) |
2009 |
8% |
$3,000 |
Patent protected until 2025 |
| NDC 54436-0112 (Proposed) |
2020s |
Estimated 4-6% |
Potential $2,800 |
Patent eligibility until 2035 |
Market Entry and Adoption
Late entry into the market with a biosimilar or innovative formulation could influence penetration. The drug’s regulatory status, orphan drug designation, or reimbursement policies will also affect uptake.
Price Projections
Current Price Benchmarks
- Biologic drugs for autoimmune conditions range from $2,200 to $3,000 per dose.
- Insurance coverages often cap out-of-pocket costs around $50-$100 for patients, but payer negotiation significantly influences net prices.
Future Price Trends
| Year |
Predicted Price per Dose |
Rationale |
| 2023 |
$2,800 |
Baseline considering market rates |
| 2025 |
$2,750 |
Patent protections extend; slight price compression due to biosimilar competition |
| 2027 |
$2,700 |
Entry of biosimilar competitors; market saturation |
| 2030 |
$2,500 |
Increased biosimilar adoption; negotiations reduce net prices |
Factors Influencing Price
- Biosimilar competition will exert downward pressure.
- Regulatory changes and patent litigation can create price volatility.
- Reimbursement policies and value-based pricing models may limit growth in list prices.
Revenue Projections
Assuming an initial market share of 4%, with 50,000 annual treated patients:
| Year |
Estimated Patients |
Market Share |
Revenue (at $2,800/dose, biannual dosing) |
Comments |
| 2023 |
50,000 |
4% |
~$140 million |
Launch year |
| 2025 |
70,000 |
6% |
~$203 million |
Growing adoption |
| 2030 |
100,000 |
8% |
~$280 million |
Market penetration |
Key Regulatory and Policy Considerations
- Pending patents expiring in 2035 could open the market to biosimilar competition.
- Changes in reimbursement policies could impact pricing and adoption.
- Orphan drug status, if applicable, could extend exclusivity and stabilize pricing.
Summary of Risks and Opportunities
- Risks: Patent challenges, biosimilar entry, price erosion, regulatory delays.
- Opportunities: Institutional uptake, label expansions, market growth in emerging regions.
Key Takeaways
- The drug is positioned within a large and growing autoimmune therapy market.
- Prices are forecasted to decline gradually due to biosimilar competition, stabilizing around $2,500 per dose by 2030.
- Revenue depends heavily on market share gains, driven by clinical differentiation and reimbursement policies.
- Patent expirations and regulatory shifts are critical determinants of long-term profitability.
FAQs
1. How does patent expiry affect price projections?
Patent expiry typically allows biosimilars to enter the market, increasing competition and reducing list prices.
2. What is the typical dosing frequency and its impact on revenue estimates?
Biologics for autoimmune conditions are often dosed biweekly or monthly, influencing per-patient revenue calculations.
3. How significant is biosimilar entry in markets where the drug is marketed?
Biosimilar entry usually reduces prices by 15-30% within 3-5 years of market entry, pressuring established biologics.
4. What are the key regulatory hurdles for this drug?
Approval depends on demonstrating biosimilarity, safety, and efficacy. Patent challenges and label expansions can delay commercialization.
5. How do reimbursement policies impact the drug’s market penetration?
Reimbursement decisions determine patient access and influence market share growth, especially if the drug is costly.
References
- Research and Markets. (2023). Global autoimmune drug market to 2030.
- U.S. Food and Drug Administration. (2022). Approved biologics.
- IQVIA. (2022). Biologic drug price and utilization data.
- FDA. (2022). Biosimilar and interchangeable biologics: regulation and guidelines.
- Medicare.gov. (2022). Reimbursement policies for biologic drugs.
